SLU-PP-332 (1000mcg) (30 Capsules)

What is SLU-PP-332?

SLU-PP-332 represents a groundbreaking compound in exercise mimetics research. This synthetic small-molecule functions as a potent estrogen-related receptor agonist. Researchers specifically study its activity at ERRα and ERRγ receptors. These receptors play crucial roles in mitochondrial function and energy metabolism.

The compound mimics molecular effects of physical exercise at the cellular level. Unlike traditional exercise enhancers, SLU-PP-332 activates exercise-response pathways directly. This novel approach creates interest in metabolic and aging research. The molecular weight of 290.3 g/mol allows efficient distribution in research models.

ERR receptors regulate genes involved in energy production and mitochondrial biogenesis. SLU-PP-332 activates these transcription factors comprehensively. The compound induces exercise-like adaptations without physical activity. This property makes it valuable for understanding exercise physiology and developing new therapeutic approaches.

The 1000mcg capsule format provides precise dosing control. Each bottle contains 30 capsules for extended study protocols. Researchers can titrate doses and investigate dose-response relationships. The potency allows investigation of effective concentrations in various models.

Understanding Estrogen-Related Receptors

Estrogen-related receptors represent important nuclear receptor family members. ERRα, ERRβ, and ERRγ comprise the three receptor subtypes. These receptors share structural similarity with estrogen receptors but have distinct functions. SLU-PP-332 primarily targets ERRα and ERRγ in research studies.

ERR receptors regulate genes involved in mitochondrial energy metabolism. They control oxidative phosphorylation, fatty acid oxidation, and mitochondrial biogenesis. These pathways determine cellular energy production and metabolic capacity. ERR activation creates exercise-like adaptations at the molecular level.

ERRα plays key roles in skeletal muscle and heart metabolism. This receptor regulates genes for fatty acid oxidation and mitochondrial function. ERRα activation enhances exercise capacity and metabolic efficiency. Research investigates SLU-PP-332’s effects on ERRα-mediated pathways.

ERRγ influences mitochondrial function across multiple tissues. This receptor regulates oxidative metabolism genes and promotes mitochondrial health. ERRγ activation improves cellular energy production and reduces metabolic dysfunction. Studies examine SLU-PP-332’s effects on ERRγ-dependent processes.

The relationship between ERR receptors and exercise physiology fascinates researchers. Exercise naturally activates ERR signaling pathways. SLU-PP-332 pharmacologically mimics these exercise-induced effects. This exercise mimetic property drives interest in metabolic and aging research applications.

SLU-PP-332’s Exercise Mimetic Properties

SLU-PP-332 demonstrates remarkable exercise-mimicking properties in preclinical models. The compound induces molecular responses similar to physical exercise. These effects occur without requiring actual physical activity. Researchers study this property for understanding exercise physiology.

Acute aerobic exercise responses emerge following SLU-PP-332 administration. Studies show ERRα-dependent activation of exercise-response genes. The compound triggers adaptations that normally require sustained physical training. This rapid induction creates interest in exercise mimetic research.

Exercise capacity improves significantly in animal models receiving SLU-PP-332. Treated subjects demonstrate enhanced endurance and performance compared to controls. These improvements stem from enhanced mitochondrial function and oxidative metabolism. The exercise-like effects occur without physical training protocols.

Molecular exercise signatures appear after SLU-PP-332 treatment. Gene expression profiles resemble those seen after physical exercise. Researchers identify similar transcriptional changes in treated and exercised subjects. This molecular mimicry provides insights into exercise adaptation mechanisms.

The concept of mimicking exercise with a pill represents groundbreaking research. SLU-PP-332 exemplifies this approach through ERR receptor activation. Potential applications range from metabolic disease to aging research. Visit the Research Hub to learn more about exercise mimetics and ERR agonists.

Mitochondrial Function and Oxidative Metabolism

Mitochondrial function represents a primary target of SLU-PP-332 research. The compound enhances mitochondrial biogenesis and function significantly. Mitochondria serve as cellular powerhouses producing ATP through oxidative phosphorylation. Enhanced mitochondrial function improves overall metabolic capacity.

Oxidative metabolism increases following SLU-PP-332 administration. Cells shift toward greater reliance on oxidative energy production. This metabolic shift improves energy efficiency and reduces metabolic waste. Researchers study these effects for metabolic disorder applications.

Fatty acid oxidation pathways respond to SLU-PP-332 treatment. Enhanced fatty acid breakdown provides efficient energy substrates. This process reduces fat accumulation and improves metabolic flexibility. Studies investigate SLU-PP-332’s effects on lipid metabolism and fat loss.

Mitochondrial biogenesis markers increase with SLU-PP-332 exposure. New mitochondrial formation enhances cellular energy production capacity. Exercise normally induces this adaptation through repeated training. SLU-PP-332 pharmacologically induces similar mitochondrial biogenesis.

Oxidative phosphorylation efficiency improves in treated models. Enhanced electron transport chain function optimizes ATP production. These improvements increase cellular energy availability and reduce oxidative stress. Research examines SLU-PP-332’s effects on mitochondrial efficiency and health.

Research Applications in Weight Loss and Metabolism

SLU-PP-332 shows significant promise for weight loss research applications. The compound demonstrates exercise-mimicking effects that reduce fat mass. Preclinical studies report substantial fat reduction with SLU-PP-332 treatment. These effects stem from enhanced oxidative metabolism and energy expenditure.

Insulin sensitivity improves with SLU-PP-332 administration in experimental models. Enhanced mitochondrial function improves glucose handling and insulin response. The compound may help reduce fat and improve insulin simultaneously. These combined effects make SLU-PP-332 valuable for metabolic syndrome research.

Metabolic syndrome biomarkers respond to SLU-PP-332 treatment. The compound improves multiple metabolic parameters associated with syndrome progression. Researchers study these effects for potential therapeutic applications in metabolic disorders. The exercise-like benefits may address multiple aspects of metabolic dysfunction.

Fat mass reduction occurs preferentially compared to lean mass. SLU-PP-332 promotes fat loss while preserving muscle tissue. This selective effect improves body composition in research models. Studies examine mechanisms underlying preferential fat metabolism.

Energy expenditure increases with SLU-PP-332 treatment. Enhanced mitochondrial function raises resting metabolic rate. This effect contributes to weight loss and fat reduction. Researchers investigate energy metabolism pathways to understand SLU-PP-332’s metabolic actions.

Indirect kidney protection emerges as an unexpected benefit. Weight loss and metabolic improvements protect kidney function. Nephrology research examines SLU-PP-332’s potential for kidney health applications. These protective effects add to the compound’s therapeutic potential.

Cardiovascular Research and Heart Failure Applications

SLU-PP-332 demonstrates significant benefits in cardiovascular research models. The compound enhances cardiac function through metabolic improvements. Heart failure research incorporates SLU-PP-332 to investigate therapeutic potential.

Cardiac fatty acid metabolism improves with SLU-PP-332 treatment. The heart normally relies on fatty acids for energy production. Enhanced fatty acid oxidation improves cardiac efficiency and function. Studies show SLU-PP-332 improves energy metabolism in failing hearts.

Mitochondrial function in cardiac tissue responds to SLU-PP-332. Enhanced mitochondrial health improves cardiac energy production and function. These improvements support better heart performance in heart failure models. Research examines SLU-PP-332’s effects on cardiac mitochondrial biology.

Heart failure outcomes improve in animal models receiving SLU-PP-332. Treated subjects show better cardiac function and survival compared to controls. Novel pan-ERR agonists ameliorate heart failure through multiple mechanisms. These findings support continued investigation for heart failure applications.

Cardiac exercise adaptations occur without physical training. SLU-PP-332 induces exercise-like changes in cardiac tissue. These adaptations improve heart function and metabolic capacity. Researchers study these effects for understanding cardiac exercise physiology.

Energy metabolism optimization represents a key benefit. The heart requires efficient energy production for optimal function. SLU-PP-332 enhances cardiac energy metabolism through ERR activation. This approach addresses metabolic components of heart failure pathophysiology.

Aging Research and Mitochondrial Health

SLU-PP-332 shows promise for aging-related research applications. Mitochondrial dysfunction contributes significantly to aging processes. The compound reverses mitochondrial dysfunction in aging tissues. These properties make SLU-PP-332 valuable for aging research.

Aging kidney function improves with SLU-PP-332 treatment. Research shows the compound reverses mitochondrial dysfunction in aged kidneys. Inflammation markers decrease alongside mitochondrial improvements. Combined effects improve kidney function in aging models.

Cell senescence relates closely to mitochondrial dysfunction. Senescent cells accumulate with age and contribute to tissue decline. SLU-PP-332 may delay senescence through mitochondrial enhancement. Researchers study these effects for longevity and anti-aging applications.

Mitochondrial health declines with normal aging. This decline impairs energy production and contributes to age-related dysfunction. SLU-PP-332 restores mitochondrial function in aged tissues. These rejuvenating effects generate interest for gerontology research.

Oxidative stress increases with aging and mitochondrial dysfunction. SLU-PP-332’s enhancement of mitochondrial function may reduce oxidative stress. Improved mitochondrial efficiency produces fewer damaging reactive oxygen species. These effects may slow aging processes.

Exercise capacity naturally declines with age. SLU-PP-332’s exercise-mimicking properties may counteract this decline. Older subjects receiving the compound show improved metabolic function. Research examines potential applications for age-related exercise intolerance.

Autophagy Regulation and Cellular Cleanup

Autophagy represents an important cellular cleanup process. This pathway removes damaged cellular components and recycles materials. SLU-PP-332 influences autophagy through TFEB pathway regulation. This effect contributes to cellular health and function.

TFEB serves as a master regulator of autophagy and lysosomal biogenesis. ERR receptors regulate TFEB expression and activity. SLU-PP-332’s ERR activation enhances TFEB-mediated autophagy. This connection reveals important mechanisms of cellular health.

Enhanced autophagy removes damaged mitochondria from cells. This selective mitochondrial autophagy, or mitophagy, improves cellular energy production. SLU-PP-332 promotes healthy mitochondrial turnover through autophagy enhancement. These effects support optimal cellular function.

Cellular cleanup processes decline with aging and dysfunction. Impaired autophagy contributes to accumulation of cellular damage. SLU-PP-332 restores autophagy function through ERR and TFEB activation. Research examines these effects for cellular rejuvenation applications.

Protein aggregation relates to autophagy dysfunction. Accumulation of misfolded proteins damages cellular function. Enhanced autophagy helps clear protein aggregates and maintain cellular health. SLU-PP-332’s effects on autophagy may protect against protein aggregation diseases.

Dosage Protocols and Administration

SLU-PP-332 dosing requires careful consideration based on research objectives. The 1000mcg capsule strength provides flexibility in protocol design. Research protocols typically utilize dosages ranging from 1000mcg to 3mg daily. The 30-capsule bottle supports various dosing strategies for studies of different durations.

Frequency of administration depends on specific research goals. Most protocols utilize once-daily dosing due to the compound’s sustained effects. The prolonged ERR activation allows convenient single daily administration in research studies. This dosing frequency supports compliance in longer-term protocols.

Timing of administration may influence research outcomes. Morning administration may align with circadian patterns of ERR activity and metabolism. Some studies prefer administration before metabolic assessments to maximize effects. Optimal timing depends on the specific research endpoints under investigation.

Capsule administration offers convenient oral delivery of SLU-PP-332. The 1000mcg strength provides precise dose control for research protocols. Oral bioavailability allows systemic administration without injection requirements. Researchers can easily track compliance with capsule-based administration.

Dose titration protocols may be appropriate for certain research designs. Starting with lower doses and gradually increasing allows assessment of response. The 1000mcg capsule strength facilitates precise titration steps. Researchers establish clear titration schedules and monitoring protocols.

Use our Peptide Calculator to determine optimal dosing for your research protocol. Note that while designed for peptides, the calculator principles apply to dosing calculations for SLU-PP-332 as well.

SLU-PP-332 Safety Profile and Side Effects

Research on SLU-PP-332 reveals important safety considerations. The compound remains in preclinical investigation stages. Understanding the safety profile is crucial for research design and interpretation.

Mitochondrial enhancement represents a double-edged sword. While beneficial for metabolic function, excessive mitochondrial activity could increase oxidative stress. Researchers monitor markers of oxidative damage in SLU-PP-332 studies. Appropriate dosing balances benefits with potential risks.

Cardiovascular effects require careful monitoring. Enhanced cardiac metabolism may influence heart rate and blood pressure. Research protocols include cardiovascular parameter assessments. Studies track both beneficial effects and potential adverse cardiovascular outcomes.

Metabolic changes occur rapidly with SLU-PP-332 treatment. Shifts in energy metabolism and substrate utilization require monitoring. Researchers assess glucose levels, lipid profiles, and metabolic markers. Comprehensive metabolic monitoring ensures safety in study protocols.

Long-term safety data remains limited due to preclinical status. Chronic administration studies continue to assess extended effects. Researchers implement thorough safety monitoring for longer-term protocols. Systematic tracking of adverse events informs safety profile development.

Contraindications and precautions require consideration in research design. Subjects with certain medical conditions may require exclusion criteria. Medication interactions should be evaluated before study enrollment. Pregnancy and breastfeeding represent standard exclusion criteria for research compounds.

Combination Protocols with Metabolic Compounds

SLU-PP-332 may be combined with other metabolic research compounds. Combination approaches can target multiple pathways simultaneously. This strategy may provide synergistic benefits beyond single-compound administration in research models.

Mitochondrial peptides like MOTS-C 40mg complement SLU-PP-332’s actions. MOTS-C improves mitochondrial function through distinct pathways. Combined activation creates comprehensive mitochondrial enhancement. The combination addresses ERR signaling and peptide-mediated mitochondrial regulation.

NAD+ boosters like NAD+ 1000mg support mitochondrial energy production. NAD+ participates in mitochondrial oxidative phosphorylation and energy metabolism. Enhanced NAD+ levels support SLU-PP-332’s mitochondrial enhancement effects. This combination addresses ERR activation and NAD+-dependent mitochondrial processes.

5-Amino-1MQ works through different metabolic enhancement pathways. This compound inhibits NNMT to boost NAD+ levels and enhance metabolism. Combining with SLU-PP-332 may provide complementary effects on mitochondrial function. The combination addresses ERR signaling and NAD+-dependent metabolic pathways.

Exercise-enhancing compounds may offer additional research insights. Other exercise mimetics or performance enhancers could complement SLU-PP-332’s effects. Research examines whether combination approaches enhance exercise-like benefits beyond monotherapy. These combinations require careful evaluation of potential interactions.

Combination protocols require careful consideration of dosing and timing. Researchers must evaluate potential interactions between compounds. Separate administration times may optimize absorption and minimize potential competition. The 1000mcg capsule format facilitates precise combination dosing protocols.

Comparison to Other Exercise Mimetics

SLU-PP-332 represents a novel approach to exercise mimetics research. Other compounds attempt to mimic exercise through different mechanisms. Comparison reveals unique advantages and properties of SLU-PP-332.

AMPK activators represent another class of exercise mimetics. These compounds activate AMPK pathways that respond to energy stress. SLU-PP-332 works through ERR receptors rather than AMPK activation. Researchers compare efficacy and mechanisms between these approaches.

PPAR agonists also influence metabolic pathways similar to exercise. PPARδ activation enhances fatty acid oxidation and endurance. SLU-PP-332’s ERR activation provides complementary yet distinct metabolic effects. Comparative studies examine which pathways produce optimal exercise-like benefits.

Traditional exercise remains the gold standard for health benefits. Pharmacological mimetics attempt to replicate some exercise effects. SLU-PP-332 provides specific molecular exercise adaptations without comprehensive physical benefits. Research examines how closely pharmacological approaches mimic actual exercise.

Natural exercise activates multiple integrated pathways. Single-compound mimetics target specific exercise-response mechanisms. SLU-PP-332 focuses on ERR-mediated mitochondrial adaptations. This targeted approach may miss other exercise benefits through different pathways.

Combination approaches may better replicate comprehensive exercise effects. Targeting multiple exercise-response pathways could create more complete mimetics. Research explores whether SLU-PP-332 combinations better mimic full exercise adaptations. These approaches represent future directions in exercise mimetics research.

Preclinical Research Summary and Future Directions

Preclinical investigations reveal extensive SLU-PP-332 research findings. Cellular assays demonstrate significant ERRα/ERRγ activation and downstream effects. Animal models show enhanced exercise capacity and metabolic improvements. These preclinical results support continued investigation of SLU-PP-332’s potential.

Gene expression studies reveal exercise-like transcriptional signatures. SLU-PP-332 induces genes involved in mitochondrial function and oxidative metabolism. These expression patterns closely resemble those seen after physical exercise. Research continues to map comprehensive gene expression profiles following treatment.

Heart failure research demonstrates promising outcomes in animal models. Pan-ERR agonists improve cardiac function and survival. Enhanced fatty acid metabolism and mitochondrial function contribute to benefits. Clinical translation represents an important future direction for cardiovascular applications.

Aging research incorporates SLU-PP-332 for mitochondrial rejuvenation. Reversal of mitochondrial dysfunction in aged tissues shows therapeutic potential. Kidney protection and reduced inflammation add to aging research applications. Studies examine potential for age-related metabolic and functional decline.

Exercise intolerance research investigates SLU-PP-332’s therapeutic potential. Loss of skeletal muscle ERR receptors leads to severe exercise intolerance. SLU-PP-332’s ERR activation may address this underlying cause. Research explores applications for conditions with limited exercise capacity.

Future research directions include mechanism refinement and clinical translation. Understanding precise pathways and optimal dosing remains ongoing. Researchers investigate long-term safety and efficacy in diverse populations. Clinical trials will determine translational potential for various applications.

Frequently Asked Questions

1. What is SLU-PP-332 and how does it work as an exercise mimetic?

SLU-PP-332 is a synthetic small-molecule compound that functions as a potent estrogen-related receptor (ERR) agonist with selective activity at ERRα and ERRγ. The compound mimics the molecular effects of exercise by activating ERR signaling pathways that regulate mitochondrial function, oxidative metabolism, and energy production. SLU-PP-332 induces ERRα-dependent acute aerobic exercise responses and enhances exercise capacity in preclinical models without requiring physical activity. The compound activates transcriptional programs associated with mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation, creating exercise-like adaptations at the cellular level.

2. What are the primary research applications of SLU-PP-332?

SLU-PP-332 demonstrates significant research potential across multiple domains including exercise mimetics research, mitochondrial function studies, metabolic enhancement and weight loss protocols, heart failure research, aging and mitochondrial dysfunction, and autophagy regulation studies. The compound shows promise for reducing fat mass and improving insulin sensitivity through exercise-mimicking effects. Additional applications include cardiac fatty acid metabolism enhancement, aging kidney protection, and exercise capacity enhancement in models with limited physical function. The comprehensive ERR activation creates broad research potential across metabolic and aging-related fields.

3. What is the recommended SLU-PP-332 dosage for research studies?

Most research protocols utilize SLU-PP-332 dosages ranging from 1000mcg to 3mg daily. The 1000mcg capsule strength provides flexibility for protocol design and dose titration. Due to the compound’s sustained effects on ERR signaling, most protocols recommend once-daily administration. The 30-capsule bottle provides sufficient supply for various study durations depending on dosing frequency. Morning administration typically aligns with circadian patterns of ERR activity and metabolism, though optimal timing depends on specific research endpoints. Always consult established research protocols and use our Peptide Calculator to determine optimal dosing for your specific study design.

4. How does SLU-PP-332 enhance mitochondrial function and oxidative metabolism?

SLU-PP-332 enhances mitochondrial function through ERRα and ERRγ receptor activation. These receptors regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation. Treatment increases markers of new mitochondrial formation and enhances oxidative metabolism efficiency. Cells shift toward greater reliance on oxidative energy production, improving energy efficiency and reducing metabolic waste. Enhanced electron transport chain function optimizes ATP production and reduces oxidative stress. Fatty acid oxidation pathways respond by providing efficient energy substrates, reducing fat accumulation and improving metabolic flexibility.

5. What effects does SLU-PP-332 demonstrate on weight loss and metabolism?

Research demonstrates significant weight loss potential through SLU-PP-332’s exercise-mimicking effects. Preclinical studies show substantial fat mass reduction with treatment. The compound improves insulin sensitivity and glucose handling alongside fat reduction. Metabolic syndrome biomarkers improve across multiple parameters. Energy expenditure increases through enhanced mitochondrial function, raising resting metabolic rate. Importantly, fat loss occurs preferentially while lean mass is preserved, improving body composition. Indirect kidney protection emerges as an additional benefit through weight loss and metabolic improvements.

6. Can SLU-PP-332 be combined with other metabolic research compounds?

Yes, SLU-PP-332 may be combined with other metabolic research compounds to target multiple pathways simultaneously. Combining with MOTS-C 40mg addresses both ERR signaling and peptide-mediated mitochondrial regulation. NAD+ 1000mg supports mitochondrial energy production alongside SLU-PP-332’s ERR activation. 5-Amino-1MQ provides complementary NNMT inhibition and NAD+ boosting for comprehensive metabolic enhancement. Other exercise mimetics or performance enhancers may offer additional research insights. Combination protocols require careful consideration of dosing, timing, and potential interactions. The 1000mcg capsule format facilitates precise combination dosing.

7. What cardiovascular benefits does SLU-PP-332 demonstrate in research?

SLU-PP-332 shows significant benefits in cardiovascular research, particularly in heart failure models. The compound enhances cardiac fatty acid metabolism, improving the heart’s primary energy source efficiency. Mitochondrial function in cardiac tissue improves, supporting better cardiac energy production and function. Preclinical studies show improved heart failure outcomes with treatment, including better cardiac function and survival. The compound induces exercise-like cardiac adaptations without physical training. Novel pan-ERR agonists ameliorate heart failure through enhanced cardiac fatty acid metabolism and mitochondrial function, addressing metabolic components of heart failure pathophysiology.

8. How does SLU-PP-332 influence aging and mitochondrial health?

SLU-PP-332 demonstrates promising effects for aging-related research by reversing mitochondrial dysfunction in aged tissues. Research shows the compound reverses mitochondrial dysfunction and reduces inflammation in aging kidneys, improving kidney function in aged models. The compound may delay cellular senescence through mitochondrial enhancement, as mitochondrial dysfunction contributes significantly to senescence. Enhanced mitochondrial efficiency reduces age-related oxidative stress by producing fewer damaging reactive oxygen species. Exercise capacity, which naturally declines with age, may be improved through SLU-PP-332’s exercise-mimicking properties.

9. What is the relationship between SLU-PP-332 and autophagy?

SLU-PP-332 influences autophagy through regulation of TFEB, a master regulator of autophagy and lysosomal biogenesis. ERR receptors regulate TFEB expression and activity, and SLU-PP-332’s ERR activation enhances TFEB-mediated autophagy. Enhanced autophagy removes damaged cellular components, including selective removal of damaged mitochondria through mitophagy. This improves cellular energy production and supports optimal cellular function. Autophagy enhancement helps clear protein aggregates and may protect against protein aggregation diseases. As autophagy declines with aging and dysfunction, SLU-PP-332 may help restore autophagy function.

10. What distinguishes SLU-PP-332 from other exercise mimetics?

SLU-PP-332 differs from other exercise mimetics through its specific mechanism targeting ERRα and ERRγ receptors. While AMPK activators work through energy stress pathways and PPAR agonists influence metabolic pathways through different receptors, SLU-PP-332 specifically activates ERR-mediated mitochondrial adaptations. This targeted approach creates distinct effects on mitochondrial biogenesis and oxidative metabolism. Compared to traditional exercise which activates multiple integrated pathways, SLU-PP-332 focuses on specific ERR-mediated exercise-response mechanisms. Research compares which pathways produce optimal exercise-like benefits and whether SLU-PP-332 combinations better replicate comprehensive exercise adaptations.

11. What are the storage requirements for SLU-PP-332 1000mcg capsules?

SLU-PP-332 capsules should be stored in a cool, dry location away from direct sunlight to maintain potency and stability. Room temperature storage (15-25°C or 59-77°F) is typically adequate for short-term use during active research protocols. For longer storage periods, refrigeration (2-8°C or 36-46°F) may help extend shelf life and preserve compound stability. Always keep capsules in their original container with the lid tightly closed to protect from moisture and humidity. Avoid storing in bathrooms or other humid environments. Do not freeze the capsules. Check expiration dates and discard capsules showing signs of degradation or discoloration.

12. What makes SLU-PP-332 unique among ERR agonists?

SLU-PP-332’s uniqueness stems from its exercise-mimicking properties and comprehensive metabolic effects. The compound induces ERRα-dependent acute aerobic exercise responses and enhances exercise capacity without physical activity. Unlike many ERR agonists studied primarily for cancer applications, SLU-PP-332 focuses on metabolic enhancement and exercise physiology. Research demonstrates weight loss effects with indirect kidney protection, cardiac benefits in heart failure models, and aging-related mitochondrial rejuvenation. The ability to simultaneously enhance mitochondrial function, improve metabolism, and provide organ-specific benefits creates a unique research profile. The concept of mimicking exercise with a pill through ERR activation represents a novel therapeutic approach.